• 24/7
  • Buzz
  • Startups
  • VC
  • Finance@
  • Work@
  • Innovation
  • Opinions
  • Search
  • cleanSearch
  • Accesabillty
  • calcalist logo
bycalcalist logo
  • Homepage
  • Tags search
  • Pharamceuticals

CTech 24/7

  • CyberArk, not SentinelOne, was always the goal, says Palo Alto CEO
  • Palo Alto CEO on $25B CyberArk deal: “This is the lowest our stock will be for the next five years”
  • CyberArk’s $25B exit enriches global funds, not Israelis
  • Check Point not for sale, says CEO as Palo Alto buys CyberArk for $25B
More stories in CTech

Pharamceuticals

1 stories about Pharamceuticals
  • Nasdaq. Photo: Shutterstock

    Ayala Pharmaceuticals Headed for Nasdaq IPO

    07.01.20|Golan Hazani The Israel-based cancer treatment developer wants to raise $100 million according to a $400 million company valuation

Load more
Ctech Logo
Twitter
Twitter
Facebook
Facebook
NewsLetter
Newsletter
Contact Us
Contact Us
Rss
Rss
About CTech Terms of Use Privacy Policy
Developed by YIT UI & UX by Basch_Interactive